Sophie F Wang

Practice Areas

Sophie Wang represents biotech, pharmaceutical, and technology companies in complex and high stakes intellectual property and commercial disputes across the country. She is a go-to resource for clients in the life sciences industry, including for complex patent litigation (including Hatch-Waxman and biosimilar litigation), post-grant review (PGR) and inter partes review (IPR) proceedings before the United States Patent Trial and Appeal Board (PTAB), trade secrets litigation, and contract, licensing, and other commercial disputes. Sophie also routinely advises clients on the management of their US and global patent and litigation strategies, including regularly consulting with counsel before the EPO and in the UK, Germany, and other foreign jurisdictions.

Sophie’s practice also includes regular representation of leading industry organizations in submitting amicus curiae briefs to the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit on a variety of key IP issues. She is also a frequent speaker and writer on IP-related topics and policies and has served in leadership roles in numerous organizations including the American Intellectual Property Law Association (AIPLA), the Alan D. Lourie Boston Intellectual Property American Inn of Court, and the Asian American Lawyers Association of Massachusetts (AALAM).

Sophie has extensive civil and criminal jury trial experience, having also served as a Special Assistant District Attorney in Suffolk County. She is a native speaker of Mandarin Chinese.

Professional Memberships

Chair, American Intellectual Property Law Association Amicus Committee

Board Member/Former Counselor of the Alan D. Lourie Boston Intellectual Property American Inn of Court

Board Member of the Asian American Lawyers Association of Massachusetts

PTAB Bar Association

Boston Bar Association

Former Diversity ad hoc Committee Member of the Boston Patent Law Association

Former Steering Committee Member of the Choate Women’s Network

Choate’s Diversity, Equity, and Inclusion Strategic Planning Committee